GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Goodwill-to-Asset

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Goodwill-to-Asset : 0.00 (As of Sep. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Navidea Biopharmaceuticals Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Navidea Biopharmaceuticals's Goodwill for the quarter that ended in Sep. 2023 was $0.00 Mil. Navidea Biopharmaceuticals's Total Assets for the quarter that ended in Sep. 2023 was $5.70 Mil.


Navidea Biopharmaceuticals Goodwill-to-Asset Historical Data

The historical data trend for Navidea Biopharmaceuticals's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Goodwill-to-Asset Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Navidea Biopharmaceuticals's Goodwill-to-Asset

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navidea Biopharmaceuticals's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Goodwill-to-Asset falls into.



Navidea Biopharmaceuticals Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Navidea Biopharmaceuticals's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Goodwill to Asset (A: Dec. 2022 )=Goodwill/Total Assets
=0/4.372
=0.00

Navidea Biopharmaceuticals's Goodwill to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Goodwill to Asset (Q: Sep. 2023 )=Goodwill/Total Assets
=0/5.699
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Navidea Biopharmaceuticals  (OTCPK:NAVB) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Navidea Biopharmaceuticals Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Executives
Craig Dais officer: Chief Financial Officer 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017
Dana J Moss director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jill Stefanelli director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Josh M Wilson director 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017
Scott John K Jr. director, 10 percent owner 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121
Agnieszka Winkler director C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281
Thomas F Farb director C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116
Michel Mikhail officer: Chief Regulatory Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Malcolm G Witter director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Alexander L Cappello director C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301
Amit Bhalla director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Joel H. Kaufman officer: Chief Business Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jed Latkin officer: Interim COO 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552